Effect of Camostat for Kidney Protection in Chronic Kidney Disease (CamKid).

Odense University Hospital0 个研究点目标入组 40 人开始时间: 2023年12月18日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Age>18 years., A clinical diagnosis of CKD of any course and meet the following criteria at screening: a. eGFR > 30 ml/min/1.73m2 b. U-ACR > 300 mg/g., Stable antihypertensive treatment 2 weeks before start of investigated medical drug (IMP) and maintain this treatment throughout the study., Office blood pressure at the screening session should be >120/70 mmHg and <150/90 mmHg., Capable of providing a signed informed consent and comply with study requirements., Women with childbearing potential must have a negative pregnancy test (urine hCG) at spot urine at the screening visit and should use contraception during the study and until one week after completion of study treatment.

•Treatment with Amiloride, Spironolactone, Aldosterone, or analogues., Breastfeeding., Congestive heart failure NYHA class IV, unstable or acute congestive heart failure., Recent cardiovascular events < 2 months prior to screening: a. Coronary artery revascularization. b. Acute stroke or TIA. c. Acute coronary syndrome., Allergy or hypersensitivity to the IMP., Addison’s disease., Gastric bypass operation., Lactose intolerance since lactose serves as one of the inactive ingredients in the IMP., Participation in other clinical trials within the last 30 days., Treatment with NSAIDs., Hyperkalemia > 5.0 mmol/L at screening., P-bilirubin > 25 umol/L at screening., Ongoing cancer treatment., Treatment with immunosuppressive therapy within 6 months prior to screening., History of organ transplantation., Evidence of current infection (CRP>50 or temperature > 38 C?)., Severe hepatic insufficiency classified as Child-Pugh C.

发起方